1Weber BL, Nathanson KL. Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer, 2000,36 ( 10 ) : 1193-1199.
2Miyoshi Y, Ando A, Hasegawa S, et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer, 2003,39(17) :2531-2537.
3Siegelmann Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer, 1999,79(3-4) :456-463.
4Baxter SW, Choong DY, Eccles DM, et al. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis, 2001,22 ( 2 ) :347-349.
5Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer,2000,87(2) :204-210.
6Kristensen VN, Andersen TI, Lindblom A, et al. A rare CYP19 ( aromatase) variant may increase the risk of breast cancer. Pharmacogenetics, 1998,8( 1 ) :43-48.
7Healey CS, Dunning AM, Duwcher F, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis, 2000,21 (2) : 189-193.
8Miyoshi Y, Iwao K, Ikeda N, et al. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer, 2000,89(4) :325-328.
9Ahsan H, Whittemore AS, Chen Y, et al. Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res, 2005,7( 1 ) :R71-81.
10Probst Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer, 1999,6 ( 2 ) : 165-173.
3Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer [ J]. Oncology, 2003, 64 (4) : 289 - 299.
4Goss PE, Ingle JN, Martino S, et al. A randomized trial of letm- zole in postmenopausal women after five years of tamoxifen thera- py for early-stage breast cancer[ J]. N Engl J Med, 2003, 349(3) : 1793 -1802.
5Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of ex- emestane after two to three years of tamoxifen therapy in postm- enopausal women with primary breast cancer[ J]. N Engl J Med, 2004, 350(6) : 1081 - 1092.
6Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial [ J ]. Lancet, 2002, 359(9324) : 2131 -2139.
7Banm M, Buzdar A, Cuzick J, et al. Anast~ozole alone or in com- bination with tamoxifen versus tamoxifen alone for adjuvant treat- ment of postmenopausal women with early-stage breast cancer: Results of the ATAC ( Arimidex, Tamoxifen Alone or in Combi- nation) trial efficacy and safety update analyses [ J ]. Cancer, 2003, 98(9) : 1802 -1810.
8Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastro- zole after 2 years' adjuvant tamoxifen: Combined results of ABC- SG trial 8 and ARNO 95 trial[J]. Lancet, 2005, 366(9484) : 455 - 462.
9Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-posi- tive breast cancer: updated findings from NCIC CTG MA. 17 [ J]. J Natl Cancer last, 2005, 97(17) : 1262 -1271.
10Buzdar A, Jonat W, Howell A, et al. Anastrozole a potent and se- lective Aromatase inhibitor versus megestrol acetate in postmeno- pausal women with advanced breast cancer: results of overview a- nalysis of two phase ~I trials. Arimidex Study Group [ J ]. J Clin Oncol, 1996, 14(7):2000-2011.
